RxDoctor Payments Data

Chad Deyoung, MD

Radiation Oncology · Ridgewood, NJNPI 1225063456

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,551 of the $4,248 with a category attached, or 60.0%. Brainlab, Inc. accounts for 75.9% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,712, more than ten times the $197 reported in 2019. Among radiation oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,248in general payments, 2019–2025

Across 39 payments — averaging $108.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Brainlab, Inc.$3K
  • Elekta, Inc.$436
  • Novocure Inc.$274
  • Siemens Medical Solutions USA, Inc.$212
  • Varian Medical Systems, Inc.$49
  • Myovant Sciences Inc.$19
  • plus $32 from 2 others

What the payments were for

  • Travel & lodging$2,55160%
  • Food & beverage$1,69740%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,248 in reported general payments places this provider in the 90th percentile of 132 radiation oncology providers in New Jersey.

See all radiation oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$286,179
Medicare patients
206
Services billed
2,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sucralfate23$3,698
Mometasone Furoate94$1,573

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →